Home > Regulatory Affairs
REGULATORY AFFAIRS SERVICES
BioBoston CRO provides regulatory affairs services for biotechnology, pharmaceutical, medical device, and diagnostic organizations that need a clear regulatory position, a coordinated submission plan, or experienced support for a defined regulatory workstream. Engagements can begin with one decision or support a broader program through development, submission preparation, and post-decision follow through.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
SERVICES
Support regulatory labeling strategy, content review, change assessment, cross-functional alignment, and
documentation for applicable drugs, biologics, medical devices, and diagnostics.
Use when labeling content must reflect the approved regulatory position, evidence, product risks, intended
use, or a planned change.
Plan, develop, coordinate, or review integrated safety, efficacy, performance, and clinical-evidence
summaries using approved analyses and source documents.
Use when evidence from multiple studies or datasets must be synthesized into a coherent regulatory
summary
Develop the submission strategy, content plan, sequence, responsibility model, readiness controls, and
application-management approach. .
Use when the sponsor needs one integrated plan for preparing and managing an application rather than
isolated document deadlines..
Assess classification, pathway options, authority expectations, evidence implications, and the strategic
route to the intended market.
Use when the route is uncertain, several options must be compared, or the current development plan may
not support the intended pathway.
Clarify the purpose, questions, evidence gaps, meeting type, internal decision owners, and follow-through plan. FDA Briefing Book Writing owns authoring of the meeting package.
Assess the current program, documents, evidence, commitments, and readiness against the defined regulatory objective and produce a prioritized action plan.
Coordinate a defined regulatory workstream, responsibilities, milestones, issues, and cross-functional decisions without replacing sponsor accountability.
Common Triggers
Desired outcomes
Define the question, relevant pathway or requirement, assumptions, options, dependencies, and unresolved risks.
Create a practical sequence, content inventory, responsibility model, gap plan, and review path before a deadline becomes the only organizing principle.
Connect regulatory decisions with clinical, technical, quality, statistical, data, labeling, and writing activities.
Maintain a reviewable record of the regulatory position, supporting evidence, decisions, and changes over time.
RELATED SERVICES
Author clinical and regulatory documents through a controlled source-review, drafting, comment-resolution, and quality-control process.
Develop the submission documents and Common Technical Document modules defined by the approved submission strategy and content plan.
Connect the regulatory route with the broader clinical development roadmap, study concepts, endpoints, vendor strategy, and early budget assumptions.
Assess oversight, quality management, audit, inspection-readiness, CAPA, and Trial Master File controls supporting the clinical program.
Coordinate milestones, dependencies, responsibilities, vendor interfaces, budgets, issues, and decisions across the regulatory plan.
deliverables
Approach
BioBoston starts with the product, intended market, development stage, prior authority history, target
decision, available evidence, and sponsor constraints. The engagement is then scoped around a specific
regulatory decision or controlled workstream rather than a generic promise to manage everything.
The sponsor remains responsible for regulatory decisions, representations, submissions, and authority
interactions. BioBoston can analyze options, facilitate cross-functional input, develop plans and
documents, identify gaps, and support execution through the sponsor’s governance and approval process.
Process
1. Confirm the product, intended market, development stage, regulatory question, target milestone, prior interactions, stakeholders, and available materials.
2. Review applicable evidence, documents, assumptions, commitments, risks, and dependencies; issue a focused gap and decision list.
3. Develop the regulatory position, pathway assessment, submission plan, labeling package, summary plan, or meeting strategy included in scope.
4.Coordinate clinical, nonclinical, CMC, quality, statistics, data, safety, medical-writing, and project input through designated decision owners.
5.Resolve comments, document the rationale, perform the agreed quality checks, and prepare sponsor approval materials.
6.Support the next controlled step, such as authoring, publishing, authority interaction, response preparation, implementation, or post-decision follow-through.
Regulatory consulting is most useful when the team needs a defensible interpretation of requirements, a practical sequence of actions, and clear ownership across clinical, technical, quality, and writing workstreams.
Add senior regulatory judgment for a defined product, pathway, authority interaction, application, or development decision without building permanent capacity first.
Bring targeted experience into a new product type, difficult evidence issue, labeling need, submission gap, or upcoming authority milestone.
Align clinical, nonclinical, quality, CMC, statistics, data, medical writing, and project-management work around the same regulatory assumptions.
Expertise
Regulatory expertise should match the product type, jurisdiction, development stage, authority question,
application type, evidence issue, and functional interfaces. Present the selected consultant through an
approved profile tied directly to the scope rather than broad claims.
RESOURCES
A planned guide to classification, evidence, authority interaction, assumptions, risks, and decision records.
A planned checklist for content inventory, responsibilities, source readiness, dependencies, review cycles, publishing, and readiness governance.
A planned buyer guide for product fit, role clarity, deliverables, communication, independence, and sponsor accountability.
FAQs
The approved CRO structure includes broad regulatory consulting plus focused services for Labeling
Support, Safety and Efficacy Summaries, Submission Planning, and Regulatory Pathway. Authority
meeting strategy and targeted regulatory gap reviews may also be scoped without creating additional Tier 2 pages.
Submission Planning owns strategy, sequencing, content planning, readiness, responsibilities, and
application management. Submission Writing owns authoring and development of the submission
documents and Common Technical Document modules defined by that plan.
BioBoston can evaluate the requested product type and regulatory question during intake. The public page should describe biotechnology, pharmaceutical, medical-device, and diagnostic support conservatively and match each engagement to approved, relevant expertise.
Regulatory Affairs can support meeting strategy, objectives, questions, evidence gaps, and follow-through. Medical Writing – FDA Briefing Book Writing owns authoring of the meeting package. The two workstreams should be coordinated but not presented as the same service.
No. Regulatory support can improve analysis, planning, documentation, and readiness, but the sponsor remains responsible for its decisions and representations, and authorities determine their own questions and outcomes.
Useful inputs include product type, intended use or indication, development stage, markets, prior authority interactions, current plans and submissions, evidence available, target milestone, known gaps, and the decision owners.
PROJECT FORM
Share the product type, development stage, intended market, regulatory question, prior authority history, and target milestone. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A useful first discussion focuses on the product, intended market, current stage, prior interactions, available evidence, unresolved question, and next milestone. BioBoston can then identify the correct service owner, consultant profile, deliverables, and cross-functional dependencies.
